Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov 19;5(11):1085-96.
doi: 10.1021/cn500083e. Epub 2014 Aug 29.

Targeting TRP channels for novel migraine therapeutics

Gregory Dussor  1 , J Yan, Jennifer Y Xie, Michael H Ossipov, David W Dodick, Frank Porreca
Affiliations
Review

Targeting TRP channels for novel migraine therapeutics

Gregory Dussor et al. ACS Chem Neurosci. .

Abstract

Migraine is increasingly understood to be a disorder of the brain. In susceptible individuals, a variety of "triggers" may influence altered central excitability, resulting in the activation and sensitization of trigeminal nociceptive afferents surrounding blood vessels (i.e., the trigeminovascular system), leading to migraine pain. Transient receptor potential (TRP) channels are expressed in a subset of dural afferents, including those containing calcitonin gene related peptide (CGRP). Activation of TRP channels promotes excitation of nociceptive afferent fibers and potentially lead to pain. In addition to pain, allodynia to mechanical and cold stimuli can result from sensitization of both peripheral afferents and of central pain pathways. TRP channels respond to a variety of endogenous conditions including chemical mediators and low pH. These channels can be activated by exogenous stimuli including a wide range of chemical and environmental irritants, some of which have been demonstrated to trigger migraine in humans. Activation of TRP channels can elicit CGRP release, and blocking the effects of CGRP through receptor antagonism or antibody strategies has been demonstrated to be effective in the treatment of migraine. Identification of approaches that can prevent activation of TRP channels provides an additional novel strategy for discovery of migraine therapeutics.

Keywords: TRP channels; TRPA1; TRPM8; TRPV1; TRPV4; migraine.

PubMed Disclaimer

References

    1. Vos T.; Flaxman A. D.; Naghavi M.; Lozano R.; Michaud C.; Ezzati M.; Shibuya K.; Salomon J. A.; Abdalla S.; Aboyans V.; Abraham J.; Ackerman I.; Aggarwal R.; Ahn S. Y.; Ali M. K.; AlMazroa M. A.; Alvarado M.; Anderson H. R.; Anderson L. M.; Andrews K. G.; Atkinson C.; Baddour L. M.; Bahalim A. N.; Barker-Collo S.; Barrero L. H.; Bartels D. H.; Basáñez M.-G.; Baxter A.; Bell M. L.; Benjamin E. J.; Bennett D.; Bernabé E.; Bhalla K.; Bhandari B.; Bikbov B.; Abdulhak A. B.; Birbeck G.; Black J. A.; Blencowe H.; Blore J. D.; Blyth F.; Bolliger I.; Bonaventure A.; Boufous S.; Bourne R.; Boussinesq M.; Braithwaite T.; Brayne C.; Bridgett L.; Brooker S.; Brooks P.; Brugha T. S.; Bryan-Hancock C.; Bucello C.; Buchbinder R.; Buckle G.; Budke C. M.; Burch M.; Burney P.; Burstein R.; Calabria B.; Campbell B.; Canter C. E.; Carabin H.; Carapetis J.; Carmona L.; Cella C.; Charlson F.; Chen H.; Cheng A. T.-A.; Chou D.; Chugh S. S.; Coffeng L. E.; Colan S. D.; Colquhoun S.; Colson K. E.; Condon J.; Connor M. D.; Cooper L. T.; Corriere M.; Cortinovis M.; de Vaccaro K. C.; Couser W.; Cowie B. C.; Criqui M. H.; Cross M.; Dabhadkar K. C.; Dahiya M.; Dahodwala N.; Damsere-Derry J.; Danaei G.; Davis A.; De Leo D.; Degenhardt L.; Dellavalle R.; Delossantos A.; Denenberg J.; Derrett S.; Des Jarlais D. C.; Dharmaratne S. D.; Dherani M.; Diaz-Torne C.; Dolk H.; Dorsey E. R.; Driscoll T.; Duber H.; Ebel B.; Edmond K.; Elbaz A.; Ali S. E.; Erskine H.; Erwin P. J.; Espindola P.; Ewoigbokhan S. E.; Farzadfar F.; Feigin V.; Felson D. T.; Ferrari A.; Ferri C. P.; Fèvre E. M.; Finucane M. M.; Flaxman S.; Flood L.; Foreman K.; Forouzanfar M. H.; Fowkes F. G. R.; Franklin R.; Fransen M.; Freeman M. K.; Gabbe B. J.; Gabriel S. E.; Gakidou E.; Ganatra H. A.; Garcia B.; Gaspari F.; Gillum R. F.; Gmel G.; Gosselin R.; Grainger R.; Groeger J.; Guillemin F.; Gunnell D.; Gupta R.; Haagsma J.; Hagan H.; Halasa Y. A.; Hall W.; Haring D.; Haro J. M.; Harrison J. E.; Havmoeller R.; Hay R. J.; Higashi H.; Hill C.; Hoen B.; Hoffman H.; Hotez P. J.; Hoy D.; Huang J. J.; Ibeanusi S. E.; Jacobsen K. H.; James S. L.; Jarvis D.; Jasrasaria R.; Jayaraman S.; Johns N.; Jonas J. B.; Karthikeyan G.; Kassebaum N.; Kawakami N.; Keren A.; Khoo J.-P.; King C. H.; Knowlton L. M.; Kobusingye O.; Koranteng A.; Krishnamurthi R.; Lalloo R.; Laslett L. L.; Lathlean T.; Leasher J. L.; Lee Y. Y.; Leigh J.; Lim S. S.; Limb E.; Lin J. K.; Lipnick M.; Lipshultz S. E.; Liu W.; Loane M.; Ohno S. L.; Lyons R.; Ma J.; Mabweijano J.; MacIntyre M. F.; Malekzadeh R.; Mallinger L.; Manivannan S.; Marcenes W.; March L.; Margolis D. J.; Marks G. B.; Marks R.; Matsumori A.; Matzopoulos R.; Mayosi B. M.; McAnulty J. H.; McDermott M. M.; McGill N.; McGrath J.; Medina-Mora M. E.; Meltzer M.; Memish Z. A.; Mensah G. A.; Merriman T. R.; Meyer A.-C.; Miglioli V.; Miller M.; Miller T. R.; Mitchell P. B.; Mocumbi A. O.; Moffitt T. E.; Mokdad A. A.; Monasta L.; Montico M.; Moradi-Lakeh M.; Moran A.; Morawska L.; Mori R.; Murdoch M. E.; Mwaniki M. K.; Naidoo K.; Nair M. N.; Naldi L.; Narayan K. M. V.; Nelson P. K.; Nelson R. G.; Nevitt M. C.; Newton C. R.; Nolte S.; Norman P.; Norman R.; O’Donnell M.; O’Hanlon S.; Olives C.; Omer S. B.; Ortblad K.; Osborne R.; Ozgediz D.; Page A.; Pahari B.; Pandian J. D.; Rivero A. P.; Patten S. B.; Pearce N.; Padilla R. P.; Perez-Ruiz F.; Perico N.; Pesudovs K.; Phillips D.; Phillips M. R.; Pierce K.; Pion S.; Polanczyk G. V.; Polinder S.; Pope Iii C. A.; Popova S.; Porrini E.; Pourmalek F.; Prince M.; Pullan R. L.; Ramaiah K. D.; Ranganathan D.; Razavi H.; Regan M.; Rehm J. T.; Rein D. B.; Remuzzi G.; Richardson K.; Rivara F. P.; Roberts T.; Robinson C.; De Leòn F. R.; Ronfani L.; Room R.; Rosenfeld L. C.; Rushton L.; Sacco R. L.; Saha S.; Sampson U.; Sanchez-Riera L.; Sanman E.; Schwebel D. C.; Scott J. G.; Segui-Gomez M.; Shahraz S.; Shepard D. S.; Shin H.; Shivakoti R.; Singh D.; Singh G. M.; Singh J. A.; Singleton J.; Sleet D. A.; Sliwa K.; Smith E.; Smith J. L.; Stapelberg N. J. C.; Steer A.; Steiner T.; Stolk W. A.; Stovner L. J.; Sudfeld C.; Syed S.; Tamburlini G.; Tavakkoli M.; Taylor H. R.; Taylor J. A.; Taylor W. J.; Thomas B.; Thomson W. M.; Thurston G. D.; Tleyjeh I. M.; Tonelli M.; Towbin J. A.; Truelsen T.; Tsilimbaris M. K.; Ubeda C.; Undurraga E. A.; van der Werf M. J.; van Os J.; Vavilala M. S.; Venketasubramanian N.; Wang M.; Wang W.; Watt K.; Weatherall D. J.; Weinstock M. A.; Weintraub R.; Weisskopf M. G.; Weissman M. M.; White R. A.; Whiteford H.; Wiersma S. T.; Wilkinson J. D.; Williams H. C.; Williams S. R. M.; Witt E.; Wolfe F.; Woolf A. D.; Wulf S.; Yeh P.-H.; Zaidi A. K. M.; Zheng Z.-J.; Zonies D.; Lopez A. D.; Murray C. J. L. (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2163–2196. - PMC - PubMed
    1. Steiner T. J.; Stovner L. J.; Birbeck G. L. (2013) Migraine: The Seventh Disabler. Headache 53, 227–229. - PubMed
    1. World Health Organization, and Lifting The Burden (2011) Atlas of Headache Disorders and Resources in the World 2011, WHO, Geneva.
    1. Hoffmann J.; Goadsby P. J. (2014) Emerging targets in migraine. CNS Drugs 28, 11–17. - PubMed
    1. Halpern A. L., and Silberstein S. D. (2005) The Migraine Attack—A Clinical Description. In Imitators of Epilepsy (Kaplan P., and Fisher R., Eds.), pp 121–132, Demos Medical Publishing, New York City.

MeSH terms

Substances